Drug Interaction Report

Abrocitinib has a major potential interaction with Bladder Cancer.

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

The inFLIXimab in Ixifi has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents. Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities. Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.

Abrocitinib has a major potential interaction with Cardiovascular Conditions and Disorders.

Deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in patients receiving abrocitinib. Patients 50 years of age and older with at least one cardiovascular risk factor, had higher rates of overall thrombosis, DVT, and PE. Avoid abrocitinib in patients that may be at increased risk of thrombosis.

Abrocitinib has a major potential interaction with Cardiovascular Conditions and Disorders.

Major adverse cardiovascular events such as cardiovascular death, myocardial infarction, and non-fatal stroke were observed in clinical studies with abrocitinib. Patients over 50 years old, current or past smokers, and patients with at least one cardiovascular risk factor were shown to have a higher risk. Consider the risks and benefits for each patient prior to initiating therapy with this drug, particularly in those that have cardiovascular risk factors including smoking.

The inFLIXimab in Ixifi has a major potential interaction with Central Nervous System Disorders.

The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barré syndrome. Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.

The inFLIXimab in Ixifi has a moderate potential interaction with COPD.

In studies, patients with moderate to severe chronic obstructive pulmonary disease (COPD) treated with infliximab developed more malignancies, the majority of lung or head and neck origin than those treated with placebo. Caution should be exercised when considering the use of infliximab in patients with moderate to severe COPD.

Abrocitinib has a major potential interaction with Heart Disease.

Major adverse cardiovascular events such as cardiovascular death, myocardial infarction, and non-fatal stroke were observed in clinical studies with abrocitinib. Patients over 50 years old, current or past smokers, and patients with at least one cardiovascular risk factor were shown to have a higher risk. Consider the risks and benefits for each patient prior to initiating therapy with this drug, particularly in those that have cardiovascular risk factors including smoking.

The inFLIXimab in Ixifi has a major potential interaction with Heart Failure.

In a study of patients with moderate to severe heart failure (New York Heart Association [NYHA] Functional Class III/IV), an increase incidence of death and hospitalization due to worsening of heart failure was observed after treatment with infliximab at 10 mg/kg. Infliximab at doses > 5 mg/kg is contraindicated in patients with moderate to severe heart failure.

Abrocitinib has a major potential interaction with History, Skin Cancer.

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

The inFLIXimab in Ixifi has a major potential interaction with History, Skin Cancer.

In clinical trials malignancies have been observed in patients receiving TNF-blockers agents. Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment. Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers. Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.

Abrocitinib has a major potential interaction with Infection.

Serious infections leading to hospitalization or death, including tuberculosis (TB) and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving JAK inhibitors such as abrocitinib. Abrocitinib should be avoided in patients with active serious infections, including localized infections. Treatment with abrocitinib is not recommended in patients with active TB, or in patients with active hepatitis B or C, as viral reactivation has been reported. Consider the risks and benefits of treatment prior to initiating therapy in patients with chronic or recurrent infections, exposed to tuberculosis, with a history of opportunistic infections, or underlying conditions that predispose to infection. Caution and close monitoring for signs and symptoms of infection is recommended during treatment.

The inFLIXimab in Ixifi has a major potential interaction with Infection.

There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers. Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections. Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections. Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.

The inFLIXimab in Ixifi has a moderate potential interaction with Infectious Hepatitis.

The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV). Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents. Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation. Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV. It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy. In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated. The safety of resuming these agents after HBV reactivation is controlled is not known. Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.

The inFLIXimab in Ixifi has a major potential interaction with Liver Disease.

Severe hepatic reactions, including acute liver failure, jaundice, hepatitis and cholestasis, have been reported with the use of infliximab. Infliximab should be discontinued if jaundice and/or marked liver enzyme elevations (e.g., greater than or equal to 5 times the upper limit of normal) develop and a thorough investigation of the abnormality should be undertaken.

Abrocitinib has a moderate potential interaction with Liver Disease.

Abrocitinib is not recommended for use in patients with severe hepatic impairment.

Abrocitinib has a major potential interaction with Lung Cancer.

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

Abrocitinib has a major potential interaction with Lymphoma.

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

The inFLIXimab in Ixifi has a major potential interaction with Lymphoma.

In clinical trials malignancies have been observed in patients receiving TNF-blockers agents. Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment. Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers. Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.

Abrocitinib has a major potential interaction with Neoplasia, Estrogen Dependent.

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

The inFLIXimab in Ixifi has a moderate potential interaction with Pancytopenia.

Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents. Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities. Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.

Abrocitinib has a moderate potential interaction with Renal Dysfunction.

Abrocitinib is not recommended for use in patients with severe renal impairment (eGFR less than 30 mL/min) and end-stage renal disease (eGFR less than 15 mL/min).

The inFLIXimab in Ixifi has a major potential interaction with Skin Cancer.

In clinical trials malignancies have been observed in patients receiving TNF-blockers agents. Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment. Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers. Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.

Abrocitinib has a major potential interaction with Smoking.

Malignancies, including lymphomas and lung cancers have been reported in patients receiving JAK inhibitors such as abrocitinib. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy, and patients who are current or past smokers.

Abrocitinib has a major potential interaction with Smoking.

Major adverse cardiovascular events such as cardiovascular death, myocardial infarction, and non-fatal stroke were observed in clinical studies with abrocitinib. Patients over 50 years old, current or past smokers, and patients with at least one cardiovascular risk factor were shown to have a higher risk. Consider the risks and benefits for each patient prior to initiating therapy with this drug, particularly in those that have cardiovascular risk factors including smoking.

The inFLIXimab in Ixifi has a major potential interaction with Tuberculosis, Active.

Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis. Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis. Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy. Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents. Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.

The inFLIXimab in Ixifi has a major potential interaction with Tuberculosis, Latent.

Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis. Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis. Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy. Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents. Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.